Association of Vitamin D Receptor Gene SNP BsmI (1544410) with Axial Spondyloarthritis in Iraqi Patients Treated with Infliximab
DOI:
https://doi.org/10.32007/jfacmedbaghdad3172Keywords:
Axial spondyloarthritis, Disease activity, Infliximab, Single nucleotide polymorphism, Tumor necrosis factor alpha, Vitamin D receptor.Abstract
Background: Axial spondyloarthritis is a chronic inflammatory disorder driven by tumor necrosis factor alpha and the interleukin-23/interleukin-17 pathway. Tumor necrosis factor alpha inhibitors such as infliximab improve outcomes, but responses vary, suggesting genetic influences; vitamin D receptor polymorphisms—particularly BsmI ( rs1544410) may modulate disease activity and therapeutic response.
Objectives: This study aimed to investigate the association between the VDR BsmI polymorphism and disease activity, as well as infliximab treatment response in patients with Axial spondyloarthritis.
Methods: A cross-sectional study was conducted on 150 AxSpA patients (108 males, 42 females) receiving
infliximab for at least three months. VDR BsmI genotyping was performed using PCR-RFLP. The study took place at the Rheumatology Clinics of Baghdad Hospital, Medical City, Iraq, with ethical approval from the Department of Biochemistry, College of Medicine, University of Baghdad. Statistical analysis included ANOVA, odds ratio estimation, and Pearson correlation, with significance defined as p ≤ 0.05.
Results: BsmI genotype distribution was AA (28%), AG (46%), and GG (26%), with allele frequencies of 51% (A) and 49% (G). No significant association was found between BsmI polymorphism and infliximab duration. However, a significant association was observed with disease activity (p = 0.008). The AA and AG genotypes were also significantly associated with male gender (p = 0.01). No significant correlations were found with other clinical features including inflammatory back pain, Urinary tract infection , enthesitis, uveitis, dactylitis, psoriasis, or colitis.
Conclusion: The GG genotType was linked to an increased likelihood of inactive disease, while the AA genotype was associated with an increased risk of low disease activity. These findings suggest VDR BsmI polymorphism may influence AxSpA disease activity and response to infliximab
References
1. Robinson PC, van der Linden S, Khan MA, Taylor WJ. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Vol. 17, Nature Reviews Rheumatology. Nature Research; 2021: 109-18. https://doi.org/10.1038/s41584-020-00552-4.
2 . Queiro R, Alonso-Castro S, Braña I, Loredo M, Pardo E, Burger S, et al. Do the Activity Indices Used in Axial Spondyloarthritis Capture the Relationships Between Obesity, Smoking and Disease Activity in the Same Way? J Clin Med. 2024 Nov 1;13(22). https://doi.org/10.3390/jcm13226801.
3. Bugaj B, Wielińska J, Świerkot J, Bogunia-Kubik K, Górna K. VDR Polymorphic Variants Are Related to Improvements in CRP and Disease Activity in Patients with Axial Spondyloarthritis That Undergo Anti-TNF Treatment. Genes (Basel). 2022 Oct 1;13(10). https://doi.org/10.3390/genes13101873.
4. Harrison SR, Marzo-Ortega H. Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?. Current Rheumatology Reports. 2023; 35: 56-67. https://doi.org/10.1007/s11926-023-01097-7.
5. Neves JSF, Vientiane JEL, Reis DM da S, Rocha Lours MA, Alves HV, Lara-Armi FF, et al. The Influence of Vitamin D Receptor Gene Polymorphisms in Spondyloarthritis. Int J Inflame. 2020; https://doi.org/10.1155/2020/8880879
6. Bouden S, Laadhar L, Messaoud M Ben, Soua J, Rouached L, I A, et al. No correlation between anti-drug antibodies and therapeutic response in Tunisian patients with chronic inflammatory diseases treated by TNF blockers. 2023. https://doi.org/10.22541/au.167271432.23314163/v1.
7. Triantos C, Aggeletopoulou I, Mantzaris GJ, Mouzaki Α. Molecular basis of vitamin D action in inflammatory bowel disease. Autoimmun Rev. 2022 Aug 1;21(8). https://doi.org/10.1016/j.autrev.2022.103136.
8. Alghamdi, A., Alahmari, M., Aljohani, K., Alanazi, A., Al Ibrahim, B., Alshowair, M., Tawfik, M., Alghamdi, W., Alanazi, S., Alzayed, F., Alghamdi, A. S., Bawazir, A., & Alhamidi, H. (2025). Prevalence and clinical implications of anti-drug antibody formation and serum drug levels among patients with IBD receiving anti-TNF therapy: A cross-sectional study. SJGastro, 31(2), 82-92. https://doi.org/10.4103/sjg.sjg_245_24.
9. Queiro R, Alonso Castro S, Braña I, et al. Analysis of disease activity in axial spondyloarthritis reveals that the obesity activity association could vary depending on the activity index chosen. Preprints.org. 2024 Oct 8. https://doi.org/10.20944/preprints202410.0545.v1.
10. Guggino, G., Rizzo, A., Mauro, D., MacAluso, F., & Ciccia, F. Gut-derived CD8 + tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients. In Annals of the Rheumatic Diseases . 2021. 80(11): 174). https://doi.org/10.1136/annrheumdis-2019-216456.
11. Navarro-Compán V, Sepriano A, Capelusnik D, Baraliakos X. Axial spondyloarthritis. The Lancet. 2025 Jan 11;405(10473):159-72. https://doi.org/10.1016/S0140-6736(24)02263-3.
12. Bugaj B, Wielińska J, Świerkot J, Bogunia-Kubik K, Górna K. VDR Polymorphic Variants Are Related to Improvements in CRP and Disease Activity in Patients with Axial Spondyloarthritis That Undergo Anti-TNF Treatment. Genes (Basel). 2022 Oct 1;13(10). https://doi.org/10.3390/genes13101873.
13. Poddubnyy D, Kiltz U, Danve A, Wright G, Haberman R, Biljan A, Clewell J, Urbanik J, Jones H, Magrey M. Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature review. Rheumatology Advances in Practice. 2025. https://doi.org/10.1093/rap/rkaf063.
14. Wielińska J, Górna K, Świerkot J, Bugaj B, Kolossa K, Jeka S, et al. Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment. Arch Immunol Ther Exp (Warsz). 2024 Jan 1;72(1). https://doi.org/10.2478/aite-2024-0023.
15. Wielińska J, Górna K, Świerkot J, Bugaj B, Kolossa K, Jeka S, et al. Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment. Arch Immunol Ther Exp (Warsz). 2024 Jan 1;72(1). https://doi.org/10.2478/aite-2024-0023.
16. Gendron E. Investigating the Association Between Alcohol Consumption and Spinal Radiographic Progression in Axial Spondyloarthritis. 2025. https://doi.org/10.2139/ssrn.5238570.
17. Mydlárová Blaščáková M, Lőrinczová Z, Anderková L, Czerwińska-Ledwig O, Mikulová Ľ, Hrušovská H, et al. Relationship Between Vitamin D Receptor Gene BsmI Polymorphism and 25-Hydroxyvitamin D Total Levels in Slovak Postmenopausal Women with Reduced Bone Mineral Density. Genes (Basel). 2025 Mar 1;16(3). https://doi.org/10.3390/genes16030337.
18. Martínez-Feito A, Novella-Navarro M, Hernández-Breijo B, Nozal P, Peiteado D, Villalba A, et al. Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. Rheumatology. 2024 Jan 4; https://doi.org/10.1093/rheumatology/kead690.
19. Hay CA, Packham J, Ryan S, Mallen CD, Chatzixenitidis A, Prior JA. Diagnostic delay in axial spondyloarthritis: a systematic review. Clinical rheumatology. 2022 Jul;41(7):1939-50. 1939-50. https://doi.org/10.1007/s10067-022-06100-7.
20. Uitterlinden AG, Fang Y, Van Meurs JBJ, Pols HAP, Van Leeuwen JPTM. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004 Sep 1;338(2):143-56. https://doi.org/10.1016/j.gene.2004.05.014.
21. You Y, Stelzl P, Joseph DN, Aldo PB, Maxwell AJ, Dekel N, et al. TNF-α Regulated Endometrial Stroma Secretome Promotes Trophoblast Invasion. Front Immunol. 2021 Nov 1;12. https://doi.org/10.3389/fimmu.2021.737401
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Abdullah H. Drewil, Manal K. Rasheed, Nizar A. Jassim
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution 4.0 International license..
